Cancer Genetics announces strategic transactions valued at $24.5M

Rutherford-based Cancer Genetics Inc., a precision medicine in oncology company, announced Monday the sale of its BioPharma business to Parsippany-based Interpace Diagnostics Group Inc. for $23.5 million.

Cancer Genetics said it sold the business unit under its junior secured lender, Partners for Growth IV L.P.

The company also announced the $1 million sale of an asset used in its clinical laboratory business to siParadigm LLC, a Pine Brook-based specialty reference laboratory focused on hematopathology and oncology diagnostics.